Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Acute Hepatitis B Assay Completes Family of Immunoassay Analyzers

By Labmedica International staff writers
Posted on 02 Aug 2011
Print article
Image: the cobas 6000 analyzer series with the cobas e 601 immunoassay module, one of the three analyzers for which the Elecsys Anti-HBc IgM Premarket Approval Application (PMA) was submitted (Photo courtesy of Roche).
Image: the cobas 6000 analyzer series with the cobas e 601 immunoassay module, one of the three analyzers for which the Elecsys Anti-HBc IgM Premarket Approval Application (PMA) was submitted (Photo courtesy of Roche).
A hepatitis B test represents the final component of the acute panel within the hepatitis menu on a family of immunoassay analyzers.

The Elecsys Anti-HBc IgM assay was developed for use on the cobas e 411, cobas e 601, and modular analytics E170 analyzers. The assay is used in the in vitro qualitative determination of IgM antibodies to hepatitis B core antigen (anti-HBc IgM) in human serum or plasma. The presence of anti-HBc IgM, in conjunction with other laboratory results and clinical information, is indicative of acute or recent Hepatitis B virus (HBV) infection.

The Roche (Basel, Switzerland) Elecsys assay will be used with the company's electrochemiluminescence (ECL) immunoassay technology. The company currently has seven other immunoassay tests available on its hepatitis menu: HBsAg, HBsAg Confirmatory, Anti-HBs, Anti-HCV, Anti-HAV, Anti-HAV IgM and Anti-HBc.

Hepatitis B is a contagious liver disease that can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. It is usually spread by blood, semen, or another body fluid from a person infected with the Hepatitis B virus. The disease can be either acute or chronic. Chronic Hepatitis B virus infection is a long-term serious illness that can result in long-term health problems, and even death.

Roche has submitted the acute hepatitis B test to the US Food and Drug and Administration (FDA; Silver Spring, MD, USA) for premarket approval. The test is not currently available for use in the United States.

Roche is a leader in in-vitro diagnostics, tissue-based cancer diagnostics, and a pioneer in diabetes management.

Related Links:

Roche
US Food and Drug and Administration



Print article
Abbott Diagnostics

Channels

Lab Tech.

view channel
Image: The nano-DLD chip (2 cm x 2 cm) mounted in a microfluidic jig. The technology allows a liquid sample to be passed, in continuous flow, through a silicon chip containing an asymmetric pillar array that allows sorting a microscopic waterfall of nanoparticles, separating particles by size down to 20 nanometer resolution (Photo courtesy of IBM Research).

Lab-on-a-Chip Technology Breaks New Bioparticle Separation Record

Scientists have developed a new lab-on-a-chip technology that can, for the first time, separate biological particles at the nanoscale down to 20 nanometers in diameter, a scale that gives access to important... Read more

Industry News

view channel

Critical Care Diagnostics Market Worth USD 1.29 Billion By 2024

The global critical care diagnostics (CCD) market will grow at a lucrative rate over the next few years to reach USD 1.29 billion by 2024, driven by the rapid awareness and acknowledgment of these tests by physicians and patients, rise in geriatric population and chronic health conditions, use of telehealth services in... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.